PL1928438T3 - Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających - Google Patents

Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających

Info

Publication number
PL1928438T3
PL1928438T3 PL06815512T PL06815512T PL1928438T3 PL 1928438 T3 PL1928438 T3 PL 1928438T3 PL 06815512 T PL06815512 T PL 06815512T PL 06815512 T PL06815512 T PL 06815512T PL 1928438 T3 PL1928438 T3 PL 1928438T3
Authority
PL
Poland
Prior art keywords
ibudilast
treating drug
drug addictions
addictions
treating
Prior art date
Application number
PL06815512T
Other languages
English (en)
Inventor
Kirk W Johnson
Linda May Rothblum Watkins
Original Assignee
Avigen Inc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc, Univ Colorado Regents filed Critical Avigen Inc
Publication of PL1928438T3 publication Critical patent/PL1928438T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL06815512T 2005-09-26 2006-09-26 Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających PL1928438T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72056805P 2005-09-26 2005-09-26
US81003806P 2006-05-31 2006-05-31
PCT/US2006/037563 WO2007038551A2 (en) 2005-09-26 2006-09-26 Use of ibudilast for treating drug and behavioral addictions
EP06815512A EP1928438B1 (en) 2005-09-26 2006-09-26 Use of ibudilast for treating drug addictions

Publications (1)

Publication Number Publication Date
PL1928438T3 true PL1928438T3 (pl) 2013-08-30

Family

ID=37806904

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06815512T PL1928438T3 (pl) 2005-09-26 2006-09-26 Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających

Country Status (12)

Country Link
US (1) US7915285B2 (pl)
EP (1) EP1928438B1 (pl)
JP (1) JP5411504B2 (pl)
AU (1) AU2006294758A1 (pl)
BR (1) BRPI0616344A2 (pl)
CA (1) CA2623072A1 (pl)
DK (1) DK1928438T3 (pl)
ES (1) ES2412858T3 (pl)
PL (1) PL1928438T3 (pl)
PT (1) PT1928438E (pl)
RU (1) RU2008116720A (pl)
WO (1) WO2007038551A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623072A1 (en) 2005-09-26 2007-04-05 Avigen, Inc. Use of ibudilast for treating drug and behavioral addictions
US20110275664A1 (en) * 2005-09-26 2011-11-10 The Regents Of The University Of Colorado,A Body Corporate Method for treating drug and behavioral addictions
WO2007142924A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
US20070281924A1 (en) * 2006-05-31 2007-12-06 Gaeta Federico C MIF inhibitors for treating neuropathic pain and associated syndromes
WO2008045641A2 (en) * 2006-10-10 2008-04-17 The University Of Chicago Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent
CA2669463A1 (en) * 2006-11-09 2008-05-15 Avigen, Inc. Method for treating delirium
JP2010513569A (ja) * 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
US20080181876A1 (en) * 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
US20100076006A1 (en) * 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
WO2009017625A1 (en) * 2007-07-27 2009-02-05 Avigen, Inc. Treatment of depression, phychosis, and anxiety
WO2009029308A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
PL2255184T3 (pl) 2008-02-28 2013-12-31 Univ Virginia Patent Foundation Gen transportera serotoniny i leczenie alkoholizmu
US9226918B2 (en) * 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
CA2785056A1 (en) * 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US20110218215A1 (en) * 2010-03-04 2011-09-08 Holly Benjamin D Compositions and Methods for Treating Social Anxiety
PL2801625T3 (pl) 2010-07-02 2018-06-29 University Of Virginia Patent Foundation Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków
AU2013201989B2 (en) * 2010-11-08 2016-01-07 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN106038567A (zh) * 2010-11-08 2016-10-26 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
JP2014525927A (ja) * 2011-08-18 2014-10-02 シャイアー アーゲー 治療法に使用される５−ｈｔ４受容体アゴニスト及びｐｄｅ４阻害剤の組合せ
EP3045173A3 (en) 2011-09-09 2016-09-14 The University of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US9610285B2 (en) 2011-11-16 2017-04-04 University Of Florida Research Foundation, Incorporated Compositions for controlling food intake and uses therefor
IN2014DN10404A (pl) * 2012-05-07 2015-08-14 Omeros Corp
NZ628130A (en) * 2012-05-07 2017-02-24 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
WO2015023871A1 (en) * 2013-08-15 2015-02-19 Medicinova, Inc. Treatment of alcoholism using ibudilast
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10188645B2 (en) * 2015-08-26 2019-01-29 Ian Cain Smith Methods and compositions for ameliorating symptoms of termination of opioid pain therapy
WO2017196857A1 (en) * 2016-05-10 2017-11-16 Medicinova, Inc. Treatment of alcoholism and depression and/or dysphoric mood using ibudilast
US20190201494A1 (en) * 2016-09-13 2019-07-04 Stc Unm Compositions and methods for treating nicotine withdrawal
US11129803B2 (en) 2017-09-18 2021-09-28 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit tolerance to opioids
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
JP3601898B2 (ja) * 1996-02-14 2004-12-15 俊隆 鍋島 薬物依存形成抑制剤
US6288234B1 (en) 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
FR2797402B1 (fr) * 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
EP1511736A4 (en) 2002-06-07 2006-06-07 Cortical Pty Ltd THERAPEUTIC MOLECULES AND METHOD 1
GB2405146A (en) 2002-06-07 2005-02-23 Cortical Pty Ltd Napthalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)
AU2003302588A1 (en) * 2002-12-03 2004-06-23 Kyorin Pharmaceutical Co., Ltd. Phosphodiesterase 10a inhibitors
WO2004058713A1 (en) 2002-12-20 2004-07-15 Irm Llc Differential tumor cytotoxocity compounds and compositions
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2005058304A1 (en) 2003-12-17 2005-06-30 Cortical Pty Ltd Implantable device containing inhibitor of macrophage migration inhibitory factor
GB0423405D0 (en) 2004-10-21 2004-11-24 Novartis Ag Organic compounds
JP4954085B2 (ja) 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
GB0507695D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
CA2623072A1 (en) 2005-09-26 2007-04-05 Avigen, Inc. Use of ibudilast for treating drug and behavioral addictions
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007142924A1 (en) 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
CA2669463A1 (en) 2006-11-09 2008-05-15 Avigen, Inc. Method for treating delirium
US20080181876A1 (en) 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain

Also Published As

Publication number Publication date
AU2006294758A1 (en) 2007-04-05
US20070072899A1 (en) 2007-03-29
DK1928438T3 (da) 2013-04-22
US7915285B2 (en) 2011-03-29
RU2008116720A (ru) 2009-11-10
WO2007038551A3 (en) 2007-06-28
EP1928438B1 (en) 2013-03-20
PT1928438E (pt) 2013-04-03
HK1120737A1 (en) 2009-04-09
JP5411504B2 (ja) 2014-02-12
JP2009509975A (ja) 2009-03-12
CA2623072A1 (en) 2007-04-05
WO2007038551A2 (en) 2007-04-05
ES2412858T3 (es) 2013-07-12
EP1928438A2 (en) 2008-06-11
BRPI0616344A2 (pt) 2011-06-14

Similar Documents

Publication Publication Date Title
PL1928438T3 (pl) Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających
GB0602178D0 (en) Therapeutic treatment
IL198663A0 (en) Tissue treatment methods
IL192299A0 (en) Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
PL2034920T3 (pl) Urządzenie do laserowych zabiegów dermatologicznych
GB0606604D0 (en) Treatment apparatus
BRPI0914294A2 (pt) aparelho de tratamento de cápsulas
EP2078536A4 (en) MEDICAL DEVICE
IL193747A0 (en) New therapeutic combinations for the treatment of depression
NO2016023I1 (no) Glycerol fenylbutyrat
ITRE20060026A1 (it) Apparecchio per trattamenti medicinali
AP2008004593A0 (en) Antivral drugs for treatment of arenavirus infection
ITRE20060127A1 (it) Apparecchio per trattamenti medicali
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
IL187715A0 (en) Use of phenylsemicarbazones for seed treatment
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
GB2452204B (en) Head worn medical treatment apparatus
GB0608655D0 (en) Therapeutic Treatment
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP1842498A4 (en) TREATMENT DEVICE FOR AN ENDOSCOPE
GB0610909D0 (en) Therapeutic treatment
ZA200904478B (en) Novel therapeutic use for treating leukaemia
SI1928438T1 (sl) Uporaba ibudilasta za zdravljenje zasvojenosti z drogami
ZA200800393B (en) Use of phenylsemicarbazones for seed treatment
GB0625112D0 (en) Apparatus for skin treatment